Literature DB >> 9649457

The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain.

R Fass1, M B Fennerty, J J Ofman, I M Gralnek, C Johnson, E Camargo, R E Sampliner.   

Abstract

BACKGROUND & AIMS: Evaluation of new patients with noncardiac chest pain (NCCP) may require a variety of costly tests. The aim of this study was to evaluate the efficacy of the omeprazole test (OT) in diagnosing gastroesophageal reflux (GERD) in patients with NCCP and estimate the potential cost savings of this strategy compared with conventional diagnostic evaluations.
METHODS: Thirty-nine patients referred by cardiologists were enrolled. Baseline symptoms were recorded, and the patients were randomized to either placebo or omeprazole (40 mg AM and 20 mg PM) groups for 7 days. Patients were crossed over to the other arm after a washout period and repeat baseline symptom assessment. All patients underwent 24-hour esophageal pH monitoring and upper endoscopy before randomization.
RESULTS: Thirty-seven patients (94.9%) completed the study. Twenty-three (62.2%) were classified as GERD positive and 14 as GERD negative. Eighteen (78%) GERD-positive patients and 2 (14%) GERD-negative patients had a positive OT (P < 0.01), yielding a sensitivity of 78.3% (95% confidence interval, 61.4-95.1) and specificity of 85.7% (95% confidence interval, 67.4-100). Economic analysis showed that the OT saves $573 per average patient evaluated and results in a 59% reduction in the number of diagnostic procedures.
CONCLUSIONS: The OT is sensitive and specific for diagnosing GERD in patients with NCCP. This strategy results in significant cost savings and decreased use of diagnostic tests.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649457     DOI: 10.1016/s0016-5085(98)70363-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  69 in total

Review 1.  Endoscopy-negative reflux disease.

Authors:  J P Galmiche; S B des Varannes
Journal:  Curr Gastroenterol Rep       Date:  2001-06

2.  Noncardiac (Unexplained) Chest Pain.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-08

3.  Laparoscopic fundoplication is the treatment of choice for gastro-oesophageal reflux disease. Antagonist.

Authors:  J P Galmiche; F Zerbib
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 4.  Oesophageal motor functions and its disorders.

Authors:  R K Mittal; V Bhalla
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

5.  Management of esophageal chest pain.

Authors:  Sami R Achem
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-10

Review 6.  Treatment of esophageal (noncardiac) chest pain: an expert review.

Authors:  Enrique Coss-Adame; Askin Erdogan; Satish S C Rao
Journal:  Clin Gastroenterol Hepatol       Date:  2013-08-28       Impact factor: 11.382

Review 7.  Diagnostic value of potent acid inhibition in gastro-oesophageal reflux disease.

Authors:  Joan Monés
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs.

Authors:  J Dent; D Armstrong; B Delaney; P Moayyedi; N J Talley; N Vakil
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 9.  Diagnostic utility of reflux disease symptoms.

Authors:  M Shaw
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 10.  Approach to managing undiagnosed chest pain: could gastroesophageal reflux disease be the cause?

Authors:  Nigel Flook; Peter Unge; Lars Agréus; Björn W Karlson; Staffan Nilsson
Journal:  Can Fam Physician       Date:  2007-02       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.